US NAT yield: where are we after 2 years?

Discussion of very recent literature, calculation of current risk of transfusion transmitted viral infections after introduction of NAT-HCV and NAT-HIV. Determination of cost/benefit of introduction of NAT. Conclusive statement that p24 antigen testing should be omitted after introducztion of NAT. – Volker Kretschmer